Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan.

Next Previous
Trial Profile

Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan; Ciclosporin; Fludarabine; Mycophenolate mofetil
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 10 Jan 2018 Biomarkers information updated
  • 05 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (NCT00619645).
  • 05 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (NCT00619645).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top